This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound WATCH-LIST MEDIUM

Psilocybin

Extended Research
Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict WATCH-LIST MEDIUM

Genuine plasticity tool with replicated human RCT signal for depression and end-of-life anxiety (Carhart-Harris 2021, Davis 2021, Goodwin 2022 COMP360 trial). Not for chronic daily use. The case for healthy-user microdosing is much weaker — Cameron 2020 + de Wit 2022 placebo-controlled trials found null effects on mood, cognition, creativity at microdose. Macrodose ("journey dose", 2-3.5 g dried mushrooms / 20-30 mg psilocybin) is where the published benefit sits. Verdict: WATCH-LIST for Dylan — not a fit for a 20yo with no depression/anxiety/PTSD indication, but worth knowing the mechanism and tracking the COMP360 + Usona Phase 3 readouts. Flips to OPTIONAL-ADD only with (a) documented indication, (b) screened psychiatric history (no personal/family bipolar or psychosis), (c) trip done in supported setting, (d) integration plan. Schedule I status means any non-clinical-trial use is felony possession in most jurisdictions.

Research pass: stub-manual
Sourcing deep dive

Schedule I in US; clinical trials only legal route. Decriminalized for personal use in Oregon, Colorado, several cities. Sclerotia legal in Netherlands. Spore syringes (legal in most US states for "microscopy") + home cultivation is the most common community route.

Verdict change log
  • 2026-06-05 — Initial verdict WATCH-LIST. Track COMP360 + Usona Phase 3. Not a fit for 20yo no-indication. (stub)
Open questions / gaps Open
  • Whether the acute plasticity window can be exploited for psychotherapy without the trip itself (5-HT2A antagonist + psychedelic = no trip; can the plasticity be dissociated from the subjective experience? — Olson lab psychoplastogen work).
  • Whether microdosing has any signal in specific subpopulations not captured by placebo-controlled trials (treatment-resistant depression non-responders to macro).

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…